[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612744":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":29,"overallOfficials":13,"centralContacts":36,"locations":42,"responsibleParty":62,"collaborators":13,"id":64,"slug":13,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":13,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":13,"enrollmentInfo":72,"targetDuration":13,"studyType":75,"phases":13,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":13,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"HBsAg clearance","HBsAg clearance is confirmed when two consecutive measurements, taken at an interval of at least 2 weeks, demonstrate HBsAg levels below the assay's lower limit of detection (\\\u003C 0.05 IU\u002FmL) as quantitatively determined by the Abbott Architect-i2000SR system with Chemiluminescent Microparticle Immunoassay (CMIA) technology.","48 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_ONLY","PROSPECTIVE","The study population is patients with chronic hepatitis B who are receiving both PegIFNα2b and nucleoside analog therapy with or without concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids.",[19,24],{"label":20,"type":13,"description":21,"interventionNames":22},"PegIFNα2b+Nucleoside analog","The patients receive both PegIFNα2b and Nucleoside analog therapy.",[23],"Drug: PegIFNα2b+Nucleoside analog",{"label":25,"type":13,"description":26,"interventionNames":27},"PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids","The patients received the concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[28],"Drug: PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids",[30,33],{"type":31,"name":20,"description":21,"armGroupLabels":32,"otherNames":13},"DRUG",[20],{"type":31,"name":25,"description":34,"armGroupLabels":35,"otherNames":13},"The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[25],[37],{"name":38,"role":39,"phone":40,"phoneExt":13,"email":41},"JinShui Pan","CONTACT","0086+059187981658","zdy20221021@gmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":52,"coordinates":53},"Point",[54,55],119.30611,26.06139,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":13,"email":61},"Anpeng Wu","0086+059187981029","fjydfyjg@163.com",{"type":63,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100612744",false,"NCT07257562","Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance","Inclusion Criteria:\n\n\\- chronic hepatitis B patients\n\nExclusion Criteria:\n\n* patients with malignancies\n* patients with other liver diseases\n* pregnancy patients","ALL","18 Years",{"count":73,"type":74},40,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance.\n\nThe study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.",[78],"Chronic Hepatitis B",[80],"Hepatitis B","2025-12-01",{"date":83,"type":84},"2025-12-02","ACTUAL",{"date":86,"type":84},"2025-06-01",{"date":88,"type":74},"2026-12-01",{"name":5,"class":6},1]